This section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentEmerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session
Sign In or Create an Account
or View more offersArticle contentNew epidemiological research on risks associated with anxiety and depression plus five posters across clinical programArticle contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced six poster presentations at the Psych Congress taking place September 15 through 19 in New Orleans, LA.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
“This year at Psych Congress, we will share clinical findings from our DT120 Orally Disintegrating Tablet Phase 3 clinical development program in GAD and MDD, reflecting the broad potential of DT120 in the two largest psychiatric disorders,” said Dan Karlin, Chief Medical Officer, Definium Therapeutics. “We also will present new epidemiological research examining suicidal ideation in anxiety, depression, and comorbid populations, adding to the growing body of research needed to better understand suicide risk. We are proud to contribute to this important conversation during National Suicide Prevention Awareness Month.”
Article contentArticle content
All poster presentations will take place on Thursday, September 17, from 1:15 PM – 3:30 PM CDT and Friday, September 18, from 1:15 PM – 3:30 PM CDT.
Article content
Additional Congress activities include Definium’s medical affairs booth located at #912, and details of the poster presentations are as follows:
Article content
Title
Session/Location
Invited Oral Presentation
Latest Discoveries & Emerging Trends in MDD
Thursday, September 17th
9:00 AM – 10:00 AM CDT
Great Hall A
Posters
Poster #
Phase 3 Topline Results of DT120 (lysergide) in Generalized Anxiety Disorder
195
Poster Hall
Phase 3 Topline Results of DT120 (lysergide) in Major Depressive Disorder
115
Poster Hall
DT120 (lysergide) Safety Profile from Phase 1 and Phase 2 Clinical Studies
198
Poster Hall
Phase 3 trial design and methodology: treatment with DT120 (lysergide) in Generalized Anxiety Disorder (GAD) & Major Depressive Disorder (MDD)
196
Poster Hall
Suicidal Ideation Frequency Across Generalized Anxiety Disorder, Major Depressive Disorder, and Comorbid Cohorts: The Roles of Symptom Severity, Diagnosis, and Undetected Disorder Burden
192
Poster Hall
DT120 for Major Depressive Disorder: Number Needed to Treat (NNT) and Number Needed to Harm (NNH)
125
Poster Hall
Article contentAbout Definium TherapeuticsArticle content
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article contentForward-Looking StatementsArticle content
Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the broad potential of DT120 in the two largest psychiatric disorders. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of the Company’s product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection for the Company’s product candidates, the Company’s expectations regarding the size of the eligible patient populations for its lead product candidates, if approved and commercialized; the Company’s ability to identify third-party treatment sites to conduct its trials and its ability to identify and train appropriate qualified healthcare practitioners to administer its treatments; the pricing, coverage and reimbursement of the Company’s lead product candidates, if approved and commercialized; the rate and degree of market acceptance and clinical utility of the Company’s lead product candidates, in particular, and controlled substances, in general as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026 and June 30, 2026, under headings such as “Special Note Regarding Forward-Looking Statements,” and “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.
Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content
https://www.businesswire.com/news/home/20260908936040/en/
Article contentArticle content
Contacts
Article contentInvestors: Article content
Article content
Gitanjali Jain
Article content
Article content
VP, Head of Investor Relations
Article content[email protected]Article contentMedia: Article content
Article content[email protected]Article content